Charles River Laboratories (CRL)

Investment Committee Summary

Investment Thesis

At $302 (10 October 2026) Charles River trades on roughly 27x forward earnings, a multiple that discounts an orderly mid-cycle recovery: biopharma research spending re-accelerating, discovery and safety-assessment demand normalising, and an operating margin drifting back toward 12% (reported GAAP, TTM to Jun 2026). The disagreement is not about the multiple but about the earnings base and the odds of reaching it. The independent discounted cash flow anchors fair value well beneath the multiple-derived view, and the shares are trading rich to a triangulated fair value of $185, a gap of -39%, with the probability-weighted expected value at $206 and the twelve-month target set from it at $212. The distribution is skewed left: the structural and recession rungs together carry more than a third of the weight, and peer-multiple support is offset by thinner margins and net debt of ~$2.9B. The SELL rating follows. One caution on the inputs: the recorded price sits above the range the engine holds for the past year, so the valuation gap should be re-verified against a second price source before it is acted on. The clearest way to be wrong is a durable contraction in biopharma funding that turns this cyclical soft patch into a structural reset, driving earnings and the multiple toward the structural target beneath the 52-week low.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($302) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The highest-probability bear case treats current weakness as a reset, not a dip. Biotech venture funding and large-pharma research budgets have contracted together, and contract-research demand lags those decisions by several quarters. If net book-to-bill in discovery and safety assessment stays below parity, that franchise loses pricing power just as non-human-primate supply normalises and Chinese capacity overhangs the market. Bioprocessing destocking compounds the revenue pressure. In that world an operating margin near 12% (reported GAAP, TTM to Jun 2026) compresses well below itself, the growth premium the market once paid for a research-services compounder evaporates, and the multiple de-rates alongside the earnings — the two move together rather than in sequence. The structural target, beneath the 52-week low, is the logical endpoint of that mechanism rather than a tail, and net debt of ~$2.9B limits the capacity to repurchase stock into the decline.

Key Debate

P/E Multiple explains 50% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

What the Market Is Pricing In

At the current price, the market pays 26.6× consensus forward EPS, vs the house DCF terminal 16.0×, and a peer median 22.6×. The house DCF sits 51% below spot, so the market is pricing in more than the house case — roughly 4.1pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily growth-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Biopharma-Funding / China / Bioprocessing Reset' downside ($92.50) to a 'Bull — Re-Rate' bull case ($376); the probability-weighted blend (PWEV $206) is -32% versus spot.

SBC charge: scenario targets are gross per-share prices; the PWEV is reduced by one year of stock-based-compensation dilution (1.5% of shares, on SBC ≈ 2% of revenue), trimming the gross PWEV of $209 to $206 (-1.5%). SBC is charged once, as dilution — never also deducted from FCF.

Scenario rationale — the driver path behind every target:

• Structural — Biopharma-Funding / China / Bioprocessing Reset (20%, $92.50). Structural impairment — biopharma-funding / China / demand reset: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• R&D-Spend Recession (17%, $159). Cyclical downturn — biopharma R&D & commercial budgets + consumable/service pull-through weakens for 1–2 years before normalising.
• Base — Tools + Services Growth (35%, $212). Mid-cycle — normalised biopharma R&D & commercial budgets + consumable/service pull-through; disciplined capital allocation; steady returns.
• Growth — Bioprocessing / Biologics Recovery (20%, $297). Upside — biopharma spend recovery + mix lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Re-Rate (8%, $376). Upside tail — sustained tight conditions or a structural re-rate on biopharma spend recovery + mix.

Valuation Triangulation

Four weighted anchors — an intrinsic dcf, a scenario-weighted pwev, a monte carlo median (student-t + regime switching) and a peer p/e re-rate — read them with their basis in mind. The Monte Carlo, the scenario PWEV, any DCF's exit-multiple terminal and any peer re-rate key off a market multiple, so they are not independent; only a DCF's explicit-period cash flows are multiple-free, and its terminal usually carries most of its value. The discipline is to read the spread, not to treat four numbers as four independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts is not computed, so 15% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way. The company-lever row in the Sensitivity section is an illustrative EBIT × multiple value, not a sum-of-parts anchor.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $191 and 16% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (50% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — explicit-period cash flows with an exit-multiple terminal

A 5-year cash-flow path discounted at a WACC of 8.5%, plus a terminal value of final-year FCF × 16.0x — a terminal multiple equal to 0.85 × the base multiple that the Monte Carlo and the scenario tree also use → $147. The terminal value is 75% of enterprise value, so this anchor moves with the multiple assumption. The heaviest anchor in this blend (41%); because its terminal is a market multiple, it is not independent of the multiple-driven anchors.

Peer benchmarking — relative value

Against its 4 peers in the same GICS sub-industry, re-rating to their median forward multiple (P/E 22.6x) implies $256. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so market sentiment does not set the fair value.

Across all anchors the spread is 133% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × model op-margin Δ (Δ applied to the DCF's house margin path)

Tornado — DCF/share swing by driver (widest first)

Company lever — value at the base multiple vs Life-Science Tools, Services & Software multiple (base 19.0x)

Illustrative: segment EBIT × multiple, plus net cash, over basic shares — it does not enter the triangulated fair value.

Peer Quality & Weighting

Quality-weighted forward P/E: 23.1× (simple median 22.6×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $146–$333, centre $221 (-27% vs spot); spot sits at the 83rd percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio is (triangulated FV ÷ price − 1) ÷ (1 − 'Structural — Biopharma-Funding / China / Bioprocessing Reset' target ÷ price). 'Structural — Biopharma-Funding / China / Bioprocessing Reset' ($92.50, probability 20%) is the lowest-target scenario in the tree, taken gross of SBC dilution. With a leg missing the ratio is withheld rather than computed from a magnitude. Bull case (Bull — Re-Rate): $376.

Company Overview & Business Model

Charles River Laboratories — HEALTHCARE · DIAGNOSTICS & RESEARCH. Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.

Company description as supplied by Alpha Vantage; not checked against the company's filings.

How it makes money.

† Model margin = gross margin − the opex ratio calibrated so the Monte Carlo median EPS meets the EPS target; it is not a reported operating margin.

Reported operating margin (GAAP): 12.7% for the fiscal year ended 2025-12-31; 12.3% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).

Edge. Narrow moat — CRL's edge is regulatory embeddedness (validated safety-assessment sites, NHP supply, IND-enabling data trusted by FDA) rather than a wide franchise; it is real but demand-cyclical and China/NHP-exposed. FALSIFIABLE: if DSA net book-to-bill stays below 1.0x for a year, pricing power is failing and the terminal multiple should sit near the ~16x market, not the life-science-tools ~19-23x.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

For comparison, the company's reported GAAP operating margin was 12.7% for the fiscal year ended 2025-12-31; 12.3% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 2% of revenue.

Competitive Moat

Moat sources:

• GLP-validated Safety Assessment sites with regulatory track record (switching cost + FDA familiarity)
• Non-human-primate (NHP) supply chain control and early-discovery model portfolio
• Integrated discovery-to-safety CRO breadth (fewer credible full-service competitors)
• ABSENCE of durable pricing power in RMS/China where NHP oversupply and local competition compress price

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.38 vs analyst floor +0.00 → delta +0.38 (n=29 mgmt / 21 Q&A; 42nd pctile across the S&P book, z -0.2).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 1223 articles): avg ticker sentiment +0.17 (bullish 27% / bearish 5%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-10-31 (~22d) — FY2027 organic-growth and DSA-recovery guidance framework (authored)
• 2026-11-04 (~26d) — Quarterly earnings — est. EPS $2.97 (AV EARNINGS_CALENDAR)
• 2027-01-31 (~114d) — Biopharma R&D-budget setting season read-through (large-pharma capex plans) (authored)

Forecast Track Record

• EPS surprise: beat 100% of the last 8 quarters; average surprise +8.9%.

Catalyst Timeline

6 catalysts in the next 90 days (of 14 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Scenario-macro rows withheld pending re-authoring: 1 carrying another cluster's vocabulary or a frozen figure — recorded in the narrative quarantine ledger.

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 1 bearish / 1 caution rules triggered of 5 evaluable (1 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is what the model's own rules read on this name; it does not modify the published research rating, and it is not personal financial advice.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic revenue growth (YoY, total company) below 2.0% organic (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Non-GAAP operating margin below 14.1% (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• DSA (Discovery & Safety Assessment) net book-to-bill below 1.0x (2 consecutive prints). Book-to-bill under 1.0x for two quarters means the order backlog is shrinking and forward DSA revenue and pricing are set to erode — the leading indicator of the biopharma-funding channel weakening.
• Full-year organic revenue guidance revision cut any downward revision to the FY organic range (single event). A cut to the guided FY organic range at any print signals management has lost confidence in the demand recovery embedded in the Base case, pulling the probability weight toward the recession and structural scenarios.
• China / NHP-linked revenue and pricing declining sequential decline with negative pricing commentary (2 consecutive prints). Persistent China softness and non-human-primate oversupply pressuring price is the specific channel through which the cyclical case becomes the Structural reset, where the multiple de-rates alongside earnings.

Fact / Inference / Speculation

• FACT: Spot $302; 52-week range $146–$333; engine rating SELL; house target $212 (-30%). (source: Alpha Vantage 2026-10-09, 10 October 2026)
• INFERENCE: Triangulated FV $185 (-39% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the DCF anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

48.5/100 (confidence band 33.3–63.6), 16th percentile of 893 covered names (as of 2026-10-09). Weighted composite under config ros-1.20.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 47.3 → 48.4 → 48.6 → 49.2 → 48.9 → 48.5 → 48.5 → 48.7.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $209.01.

Factor Exposures

Cross-sectional percentiles over 893 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.46, vs QQQ +0.37 (trailing ~1y daily returns).

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -32% vs spot
• Monte Carlo median implies -37% vs spot
• DCF fair value (exit-multiple terminal) implies -51% vs spot
• Bear case (Structural — Biopharma-Funding / China / Bioprocessing Reset) downside is -69% vs spot
• Net: the valuation anchor itself sits 38.7% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating warrants a Sell.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $3B + PV(terminal) $7B = EV $10B; − net debt $2.9B → equity $7B ÷ diluted shares $0.05B = $147/share (exit-multiple terminal).

• Gordon terminal → $157/share — a single-point perpetual-growth cross-check at g = 2.5% (one growth rate, not a range; it is not in the blend).
• Incremental ROIC on the forecast capex ≈ 13% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: same-sub-industry median fwd P/E → $256; EV/Rev → $421.

Weighted fair-value math

Model Calibration Caveats

Raised by the model's own checks on its run of 10 October 2026 (prices as of 2026-10-09). They concern how the model was calibrated, not the company; read the figures they touch with them in mind.

• The Monte Carlo gives only a 16% probability of the price finishing above today's; the house treats readings under 30% as a sign the downside assumptions may be too severe.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Model op margin ±3pp (76.0); Revenue CAGR ±3pp (55.0); Terminal × ±15% (46.0); Capex intensity ±15% (23.0); WACC ±1pp (17.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 16×, FY+5 revenue $5B. Triangulation leans 41% on DCF, 29% on PWEV, 18% on the Monte Carlo median, 12% on peer-implied value.